Breast cancer survivors with a history of aromatase inhibitor adjuvant therapy after a non-ablative Solid-State Vaginal Laser (SSVL) treatment reported sustained improvement in vaginal atrophy, vaginal pH, dyspareunia, sexual function and in quality of life with no serious adverse effects and with a high level of satisfaction twenty-four weeks after initial treatment in this non-randomized pilot study. The gene discussed is CYP19A1; the disease is breast cancer.